KeyCorp Boosts Danaher (NYSE:DHR) Price Target to $310.00

Danaher (NYSE:DHR) had its price target raised by KeyCorp from $290.00 to $310.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the conglomerate’s stock. KeyCorp’s price objective points to a potential upside of 20.96% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. The Goldman Sachs Group raised their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Evercore ISI raised their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $282.65.

Danaher Stock Down 1.9 %

Shares of DHR traded down $4.99 during midday trading on Wednesday, reaching $256.29. 62,069 shares of the stock were exchanged, compared to its average volume of 2,711,919. Danaher has a 52 week low of $182.09 and a 52 week high of $281.70. The company’s 50 day moving average is $270.67 and its two-hundred day moving average is $260.46. The company has a market capitalization of $189.83 billion, a P/E ratio of 43.99, a PEG ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the company earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Danaher will post 7.59 earnings per share for the current year.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Danaher

A number of large investors have recently made changes to their positions in DHR. Vanguard Group Inc. raised its stake in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Swedbank AB purchased a new stake in Danaher during the 1st quarter valued at approximately $676,545,000. TD Asset Management Inc raised its stake in Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after acquiring an additional 675,952 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Danaher by 22.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after acquiring an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC raised its stake in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.